<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11656">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984606</url>
  </required_header>
  <id_info>
    <org_study_id>1245.22</org_study_id>
    <secondary_id>2013-000060-29</secondary_id>
    <nct_id>NCT01984606</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase IIIb Randomised, Double-blind, Active-controlled, Parallel Group, Efficacy and Safety Study of Once Daily Oral Administration of Empagliflozin 25 mg Compared to Sitagliptin 100 mg During 52 Weeks in Type 2 Diabetes Mellitus Patients Who Are Treatment-naïve or on Treatment With Metformin With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Colombia:</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Mexico:</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Arab Emirates: General Authority for Health Services for Abu Dhabi</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of empagliflozin compared to
      sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on
      treatment with metformin and have insufficient glycaemic control. The study will assess
      non-inferiority of empagliflozin to sitagliptin with regards to HbA1c.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change from baseline in HbA1c after 52 weeks of treatment.</measure>
    <time_frame>Baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in bodyweight (kg) from baseline after 52 weeks of treatment</measure>
    <time_frame>Baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Systolic Blood Pressure (SBP) from baseline after 52 weeks of treatment</measure>
    <time_frame>Baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The coefficient of durability of HbA1c response between 24 weeks and 52 weeks of treatment</measure>
    <time_frame>Week 24 and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment</measure>
    <time_frame>Baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">834</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin once daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching empagliflozin</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin once daily</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching sitagliptin</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus.

          -  Male and female patients on diet and exercise regimen who are:

          -  Treatment-naïve, defined as absence of any oral antidiabetic therapy for 12 weeks
             prior to randomisation.

        or

          -  Pre-treated with immediate release metformin unchanged for 10 weeks prior to
             randomisation. Minimum dose for metformin: &gt;=1500 mg/day or maximum tolerated dose or
             maximum dose according to local label.

          -  HbA1c of &gt;= 7.5 % and &lt;= 10.5 % at Visit 1 and 3.

          -  Age &gt;= 18 yrs.

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;270 mg/dL (&gt;15 mmol/L) after an
             overnight fast during dose stabilisation (if applicable) and/or placebo run-in.

          -  Any other antidiabetic drug within 12 weeks prior to randomisation (applicable to
             treatment-naïve patients).

          -  Any other antidiabetic drug within 10 weeks prior to randomisation except metformin
             (applicable to patients on background treatment with metformin).

          -  Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or
             TIA within 3 months prior to informed consent.

          -  Indication of liver disease.

          -  Moderate to severe renal impairment.

          -  Bariatric surgery within the past two years.

          -  Treatment with anti-obesity drugs 3 months prior to informed consent.

          -  Current treatment with systemic steroids at time of informed consent or any other
             uncontrolled endocrine disorder except type 2 diabetes mellitus.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
